Lipid Regulators Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Lipid Regulators Market was valued at USD 32.4 billion in 2023 and is set to register a CAGR of 3.8% from 2024 – 2032. The lipid regulators industry is experiencing growth driven by factors such as the rising prevalence of dyslipidemia and cardiovascular disease, advancements in drug development, increased prescription rate, and growing awareness of the importance of lipid management in reducing cardiovascular risk. Also, with the growing ageing population and increasing focus on preventive healthcare, the market is expected witness lucrative growth over the coming years.
For instance, according to World Population Prospects 2022, the population aged 65 years and above is expected to rise from 10% in 2022 to 16% in 2050. As the population ages, the risk of developing dyslipidemia and cardiovascular disease also increases, thereby driving the growth of the market.
Lipid regulators, also known as lipid-lowering agents or lipid-lowering drugs, are medications used to manage abnormal levels of lipids (fats) in the blood, primarily cholesterol and triglycerides. Elevated levels of these lipids are associated with an increased risk of cardiovascular diseases such as heart attacks and strokes. Lipid regulators can help lower cholesterol and triglyceride levels, reducing the risk of these diseases.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Lipid Regulators Market size in 2023: | USD 32.4 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2023 - 2032 CAGR: | 3.8 |
2023 Value Projection: | USD 44.9 Billion |
Historical Data for: | 2018 – 2023 |
No of Pages: | 203 |
Tables, Charts & Figures: | 355 |
Segments Covered: | Type, Indication, Route of Administration, Distribution Channel, and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
The global market based on type is segmented into statins and non-statins. The statins segment dominated the global market in 2023 with 60.1% market share and is anticipated to grow at CAGR of 4.1% during the analysis period.
The market based on indication is categorized into hypercholesterolemia, hypertriglyceridemia, coronary artery disease, and other indications. The hypercholesterolemia segment accounted for highest market share and was valued at USD 13.1 billion in 2023.
The market based on route of administration is classified into oral and injectable. The oral segment held highest market share in 2023 and is anticipated to be valued at USD 37.3 billion by 2032.
Global market based on distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held majority of market share and is projected to grow at 3.7% CAGR from 2024 – 2032.
North America lipid regulators market accounted for USD 13.6 billion revenue in 2023 and is projected to reach USD 18.1 billion by 2032.
The lipid regulators industry is dynamic and multifaceted, characterized by several key players and a diverse range of lipid regulators. Competition in the global market is influenced by factors such as drug efficacy, safety, pricing, marketing strategies, and regulatory approvals. Companies strive to differentiate their products through clinical advancements, novel mechanisms of action, and strategic partnerships to gain market share and maintain a competitive edge in this dynamic and rapidly evolving market.
Prominent players operating in the lipid regulators industry include:
Market, By Type
Market, By Indication
Market, By Route of Administration
Market, By Distribution Channel
The above information is provided for the following regions and countries:
AbbVie Inc, Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb, Dr. Reddy's Laboratories Ltd., Merck & Co., Novartis AG, Pfizer, Inc., Sanofi, and Teva Pharmaceuticals.
North America market for lipid regulators accounted for USD 13.6 billion in 2023 and is projected to reach USD 18.1 billion by 2032, as the region faces a significant burden of cardiovascular disease.
The statins segment accounted for 60.1% market share in 2023 and is anticipated to record 4.1% CAGR from 2024 to 2032 as they are recommended as first-line therapy in treatment guidelines issued by organizations such as the American College of Cardiology (ACC).
The global market size for lipid regulators was valued at USD 32.4 billion in 2023 and is set to register 3.8% CAGR from 2024 to 2032, driven by the rising prevalence of dyslipidemia and cardiovascular disease, advancements in drug development, and growing awareness of the importance of lipid management in reducing cardiovascular risk.